TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Zymeworks ( (ZYME) ) is now available.
Zymeworks announced its participation in upcoming conferences, including the ASCO Gastrointestinal Cancers Symposium and the J.P. Morgan Healthcare Conference. At ASCO GI, Zymeworks will present a Trial-in-Progress poster for ZW251, an antibody-drug conjugate for hepatocellular carcinoma, while its partner Jazz will highlight the clinical profile of Ziihera® for HER2-driven gastrointestinal cancers. These presentations underscore Zymeworks’ commitment to advancing its pipeline and strengthening its position in the biotechnology industry, potentially impacting stakeholders by showcasing its innovative approaches to treating challenging diseases.
The most recent analyst rating on (ZYME) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
Zymeworks’ overall stock score is driven by strong technical momentum and positive earnings call sentiment, despite financial performance challenges and valuation concerns. The company’s revenue growth and clinical progress are promising, but profitability and cash management issues need addressing.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a global biotechnology company that manages a portfolio of licensed healthcare assets and develops a diverse pipeline of novel, multifunctional biotherapeutics. The company focuses on improving the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks employs an asset and royalty aggregation strategy to optimize future cash flows from licensed products such as Ziihera® and other product candidates. The company is known for its proprietary Azymetric™ technology and has partnerships with BeOne Medicines Ltd. and Jazz Pharmaceuticals for the development and commercialization of zanidatamab.
Average Trading Volume: 1,117,906
Technical Sentiment Signal: Buy
Current Market Cap: $1.96B
For an in-depth examination of ZYME stock, go to TipRanks’ Overview page.